Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.

Blood - 17 Dec 2020

Miao Hongzhi, Kim EunGi, Chen Dong, Purohit Trupta, Kempinska Katarzyna, Ropa James, Klossowski Szymon, Trotman Winifred, Danet-Desnoyers Gwenn, Cierpicki Tomasz, Grembecka Jolanta

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to fms-Like Tyrosine Kinase 3
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Models, Biological

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 33331926
DOI: 10.1182/blood.2020006575
PMCID: PMC7751359

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combinatorial treatment with menin and FLT3 inhibitors induces complete remission in AML models with activating FLT3 mutations.PMID 33331926Read ↗

MLL-menin and FLT3 inhibitors team up for AML.Semantic proximity Read ↗

Menin inhibitors for the treatment of acute myeloid leukemia: challenges and opportunities ahead.Semantic proximity Read ↗

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read ↗

Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibitionSemantic proximity Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged leukemia: Mechanistic insights, clinical trial progress, and potential of combination therapiesSemantic proximity Read ↗

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity Read ↗

Therapeutic implications of menin inhibition in acute leukemiasSemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Menin Inhibitors in Acute Myeloid Leukemia-What Does the Future Hold?Semantic proximity Read ↗

Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD+ Acute Myeloid Leukemia Cells.Semantic proximity Read ↗

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.